Funding secured for asbestos cancer nurse leader in Scotland
A charity that oversees specialist nurses for a type of cancer caused by exposure to asbestos has announced that it has received enough funding to maintain a key presence in Scotland.
Mesothelioma UK said the Clydebank Asbestos Group had pledged to donate sufficient funds to cover the cost of its clinical nurse specialist team leader in Scotland, Carolyn MacRae.
“Together, we aim to make a lasting impact on the lives of those affected by this rare and aggressive cancer”
Liz Darlison
Ms MacRae is a member of the Scottish Mesothelioma Network and team leader for the charity’s Scottish based clinical nurse specialists.
She is based at Queen Elizabeth University Hospital, run by NHS Greater Glasgow and Clyde, where she provides care and support for mesothelioma patients in the Glasgow and Clyde region.
Mesothelioma is a type of cancer, usually caused by exposure to asbestos and predominantly affects the lining of the lungs.
The UK has the highest incidence of the disease in the world with around 2,700 people diagnosed each year, noted Mesothelioma UK.
It is the national charity for anyone affected by mesothelioma and oversees 30 mesothelioma specialist nurses based in NHS hospitals across the UK.
The Clydebank Asbestos Group is a volunteer organisation set up in 1992 by David Colraine and his friends to help provide support, advice and information for victims of asbestos and their families.
The group works with the West Dunbartonshire Council Improving the Cancer Journey service and Macmillan Cancer Support, as well as Mesothelioma UK and the Scottish Mesothelioma Network.
Theresa Jones, chair of Clydebank Asbestos Group, said: “We are delighted to be able to allow the continuation of Carolyn and her team’s great work.
“I have known Carolyn for a number of years and here at CAG, we are looking forward to continuing our working relationship whilst also supporting the NHS,” she said.
Liz Darlison, chief executive of Mesothelioma UK, said: “This generous funding commitment from the Clydebank Asbestos Group will directly impact patient care and enhance our ability to provide critical services in Scotland.
She added: “Clydebank Asbestos Group shares our vision of improving mesothelioma care and advocating for patients.
“Together, we aim to make a lasting impact on the lives of those affected by this rare and aggressive cancer,” she said.
“Their commitment to funding this nursing post demonstrates their dedication to advancing healthcare and making a difference.”
Carolyn MacRae
